- Home
- FAX vs VALN Comparison
FAX vs VALN Comparison
Compare FAX & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FAX | VALN |
|---|---|---|
| Founded | 1986 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 594.5M | 582.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | FAX | VALN |
|---|---|---|
| Price | $12.82 | $5.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $12.25 |
| AVG Volume (30 Days) | ★ 232.6K | 21.9K |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | ★ 12.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $87.65 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.60 | $4.75 |
| 52 Week High | $16.37 | $12.18 |
Technical Indicators
Market Signals| Indicator | FAX | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 29.61 | 39.99 |
| Support Level | N/A | $5.10 |
| Resistance Level | $14.72 | $6.60 |
| Average True Range (ATR) | 0.26 | 0.20 |
| MACD | -0.04 | -0.08 |
| Stochastic Oscillator | 17.48 | 23.73 |
Price Performance
Historical ComparisonAbout FAX abrdn Asia-Pacific Income Fund Inc.
Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities and others.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.